| Website | oncomed.com |
| Category | BioTech |
| Phone | 650-995-8200 |
| bd@oncomed.com | |
| Employees | |
| Founded | 8/04 |
| TOTAL | $174M |
| FUNDING TOTAL | $174M |
| Series B, 11/08 U.S. Venture Partners Latterell Venture Partners The Vertical Group Morgenthaler Ventures Adams Street Partners DeNovo Ventures Bay Partners Nomura Phase4 Ventures | $154M |
| Venture Round, 4/11 | $20M |
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment, by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cellsâ€. They are leveraging their understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.
